An interventional study of EllaOla Kids Essentials Unflavored Powdered Multivitamin and Placebo (Tapioca Fiber) in Selective Eating, Emotional Dysregulation and Child Behavior, sponsored by EllaOla. Not yet recruiting. Open to participants aged 4 Years to 11 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by EllaOla · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn whether a daily unflavored powdered multivitamin (EllaOla Kids Essentials) improves mood and behavior in children aged 4 to 11 who are picky eaters and experience behavioral challenges. Researchers will also look at whether the multivitamin affects overall health, well-being, nutrition, and serum vitamin levels, and whether it is safe and well tolerated.
The main questions it aims to answer are:
Do more parents of children taking the multivitamin report a clinically meaningful improvement in their child's overall mood and behavior after 12 weeks than parents of children taking a placebo? Does the multivitamin change parent-reported emotional reactivity, overall health and well-being, and nutrition over 12 weeks? In children who take part in optional at-home blood testing, does the multivitamin improve serum vitamin D and vitamin B12 levels?
Researchers will compare the multivitamin to a placebo (a look-alike powder made of tapioca fiber that contains no vitamins) to see if it improves mood and behavior.
Participants will:
Be randomly assigned to receive either the multivitamin or the placebo. Neither the families nor the study team will know which one the child gets.
Have a parent or caregiver mix the powder into the child's food or drink once a day at home for 12 weeks.
Have a parent or caregiver complete short online questionnaires about the child's mood, behavior, health, and nutrition at baseline and at Weeks 2, 4, 6, 8, and 12, using a smartphone app. All study visits are remote.
Choose whether to do an optional at-home blood collection at the start and at Week 12.
Choose whether to continue in an optional 12-week open-label extension (Weeks 12-24), where all children, including those who were on placebo, receive the multivitamin.
224 studies on the registry are indexed under Child Behavior; 39 are open to participants now.
This study's planned enrollment of 166 is above the median of 140 across 197 interventional studies indexed under Child Behavior.
Browse Child Behavior studies →This is the only study on the registry with EllaOla as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any potential participants who:
Concomitant Therapies:
Other Illnesses or Conditions:
Currently enrolled in another interventional research study or plans to enroll in any other interventional research study at any point during the study's duration
a. Only one child per household may enroll in this research at a time
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive EllaOla Kids Essentials Unflavored Powdered Multivitamin, administered daily at home by the parent/caregiver for 12 weeks (double-blind core period). Participants may opt into a 12-week open-label extension (Weeks 12-24) and continue receiving the active multivitamin.
Dietary Supplement: EllaOla Kids Essentials Unflavored Powdered Multivitamin
Participants receive a matching placebo (tapioca fiber) of identical appearance, administered daily at home by the parent/caregiver for 12 weeks (double-blind core period). Participants may opt into a 12-week open-label extension (Weeks 12-24) and switch to the active multivitamin (delayed start).
Dietary Supplement: Placebo (Tapioca Fiber)
An unflavored, powdered children's multivitamin. Each serving provides vitamins A, C, D3 (20 mcg), E, K2, B1, B3, B5, B6, B12 (2 mcg), folate, and biotin, plus iodine, zinc, selenium, manganese, and a fruit and vegetable blend, in a tapioca fiber base with monk fruit. Parents/caregivers give one full serving once daily in the morning, mixed into at least 2 ounces of juice or milk, for 12 weeks. Participants who opt into the open-label extension continue daily use through Week 24.
Also known as: EllaOla Kids Essentials, Study Product
A tapioca fiber powder with no vitamins or minerals, matched to the study product in appearance, packaging, and labeling. Parents/caregivers give one full serving once daily in the morning, mixed into at least 2 ounces of juice or milk, for the 12-week double-blind period. Used as Placebo comparator only.
Also known as: Matching Placebo
Proportion of PGI-C Responders on the Overall Mood and Behavior Item
Proportion of participants rated by their parent/caregiver as "very much improved" (1) or "much improved" (2) on the Overall Mood and Behavior item of the Parent Global Impression of Change (PGI-C). The PGI-C is rated on a 7-point scale (1 = very much improved; 4 = no change; 7 = very much worse). Lower scores indicate greater improvement.
Time frame: Week 12
Proportion of PGI-C Responders on the Overall Mood and Behavior Item Over Time
Proportion of participants rated "very much improved" (1) or "much improved" (2) on the PGI-C Overall Mood and Behavior item. The 7-point scale runs from 1 = very much improved to 7 = very much worse, with 4 = no change.
Time frame: Weeks 2, 4, 6, 8, and 12
Proportion of PGI-C Improvers on the Overall Mood and Behavior Item
Proportion of participants rated "very much improved" (1), "much improved" (2), or "minimally improved" (3) on the PGI-C Overall Mood and Behavior item. The 7-point scale runs from 1 = very much improved to 7 = very much worse, with 4 = no change.
Time frame: Weeks 2, 4, 6, 8, and 12
Mean PGI-C Overall Mood and Behavior Score
Mean parent-rated score on the PGI-C Overall Mood and Behavior item. The 7-point scale runs from 1 = very much improved to 7 = very much worse, with 4 = no change. Lower scores indicate greater improvement.
Time frame: Weeks 2, 4, 6, 8, and 12
Change From Baseline in Serum 25-Hydroxyvitamin D [25(OH)D] (Blood Work Subgroup)
Change from baseline in serum 25(OH)D in the optional blood work subgroup. Samples are collected at home with the Tasso Mini device.
Time frame: Baseline and Week 12
Change From Baseline in Serum Vitamin B12 (Blood Work Subgroup)
Change from baseline in serum vitamin B12 in the optional blood work subgroup. Samples are collected at home with the Tasso Mini device.
Time frame: Baseline and Week 12
PGI-C Overall Health and Well-being: Responder Proportion and Mean Score
Proportion of participants rated "very much improved" (1) or "much improved" (2), and the mean score, on the PGI-C Overall Health and Well-being item. The 7-point scale runs from 1 = very much improved to 7 = very much worse, with 4 = no change. Lower scores indicate greater improvement.
Time frame: Weeks 2, 4, 6, 8, and 12
PGI-C Overall Nutrition: Responder Proportion and Mean Score
Proportion of participants rated "very much improved" (1) or "much improved" (2), and the mean score, on the PGI-C Overall Nutrition item. The 7-point scale runs from 1 = very much improved to 7 = very much worse, with 4 = no change. Lower scores indicate greater improvement.
Time frame: Weeks 2, 4, 6, 8, and 12
PGI-C Mood and Behavior Domain Composite Score
Mean of the two PGI-C Mood and Behavior domain items (tantrums/meltdowns and mood), along with the individual item scores. Each item is rated on a 7-point scale from 1 = very much improved to 7 = very much worse, with 4 = no change. Lower scores indicate greater improvement.
Time frame: Weeks 2, 4, 6, 8, and 12
Change From Baseline in Emotion Dysregulation Inventory (EDI) Reactivity Score
Change from baseline in the parent-reported EDI Reactivity Index score. The EDI-Young Child is used for ages 4-5 and the standard EDI for ages 6-11. Items are rated on a 5-point scale (0 = not at all to 4 = very severe) over the past 7 days. Higher scores indicate poorer emotion regulation.
Time frame: Baseline, Weeks 4, 8, and 12
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Mar 2027, 5 months later.
Of 141 interventional studies with no phase under Child Behavior, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 41. This study's planned 5 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.